Angiomyolipoma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2],Rekha, M.D.

Overview

Rapamycin and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken.^[1]

Future Therapies

Rapamycin

Rapamycin and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken.^[1]

References

↑ ^1.0 ^1.1 Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.

Template:WikiDoc Sources

[Bissler2010-1] 1.0 ^1.1 Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.

[1]